Efficacy and safety of fixed-ratio combination insulin degludec/liraglutide in type 2 diabetes: A systematic review and meta-analysis of randomised controlled trials.

Wang R, Luo S, Xiao Z, Zhou Z

Diabetes/metabolism research and reviews27 Nov 2023Cited by 2 (Europe PMC)

PMID38013215DOI10.1002/dmrr.3752PepBankPUB-38013215

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study9

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone9

In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Liraglutide.

01HumanNot a test of Liraglutide aloneSystematic reviewEfficacy outcome
In patients with type 2 diabetes, the fixed-ratio combination IDegLira lowered HbA1c versus comparators (weighted mean difference 0.52%).
In plain wordsIn people with type 2 diabetes, the insulin degludec/liraglutide combination lowered HbA1c more than the comparator treatments.
Peptide
Liraglutide
Outcome
DecreaseHbA1c reduction
Study
n: not reported in source
Comparator
Insulin, GLP-1 receptor agonists or placebo (pooled)
Outcome group
Glycemic control · Metabolic and weight
Measurements
WMD
0.52%
HbA1c
Source sentences
Summary
In terms of glycaemic efficacy, IDegLira reduced levels of glycated haemoglobin (HbA1c; weighted mean differences (WMDs) 0.52%, 95% CI 0.33%-0.71%); fasting blood glucose (0.32 mg/dL, 0.14-0.50 mg/dL), and the nine-point self-measured plasma glucose (0.25 mmol/L, 0.25-0.36 mmol/L).
1 context sentence(design, population, supporting numbers)
Summary · context
Randomized controlled trials published in English that compared IDegLira with placebo or GLP-1 agonists or insulin in patients with T2DM were selected up to December 2022.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3801321501
02HumanNot a test of Liraglutide aloneSystematic reviewEfficacy outcome
In patients with type 2 diabetes, IDegLira lowered fasting blood glucose versus comparators (0.32 mg/dL).
In plain wordsIn people with type 2 diabetes, the insulin degludec/liraglutide combination lowered fasting blood glucose more than the comparator treatments.
Peptide
Liraglutide
Outcome
DecreaseFasting blood glucose reduction
Study
n: not reported in source
Comparator
Insulin, GLP-1 receptor agonists or placebo (pooled)
Outcome group
Glycemic control · Metabolic and weight
Measurements
WMD
0.32 mg/dL
fasting blood glucose
Source sentences
Summary
In terms of glycaemic efficacy, IDegLira reduced levels of glycated haemoglobin (HbA1c; weighted mean differences (WMDs) 0.52%, 95% CI 0.33%-0.71%); fasting blood glucose (0.32 mg/dL, 0.14-0.50 mg/dL), and the nine-point self-measured plasma glucose (0.25 mmol/L, 0.25-0.36 mmol/L).
1 context sentence(design, population, supporting numbers)
Summary · context
Randomized controlled trials published in English that compared IDegLira with placebo or GLP-1 agonists or insulin in patients with T2DM were selected up to December 2022.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3801321502
03HumanNot a test of Liraglutide aloneSystematic reviewEfficacy outcome
In patients with type 2 diabetes, IDegLira lowered nine-point self-measured plasma glucose versus comparators (0.25 mmol/L).
In plain wordsIn people with type 2 diabetes, the insulin degludec/liraglutide combination lowered day-long home glucose readings more than the comparator treatments.
Peptide
Liraglutide
Outcome
DecreaseNine-point self-measured plasma glucose reduction
Study
n: not reported in source
Comparator
Insulin, GLP-1 receptor agonists or placebo (pooled)
Outcome group
Glycemic control · Metabolic and weight
Measurements
WMD
0.25 mmol/L
nine-point self-measured plasma glucose
Source sentences
Summary
In terms of glycaemic efficacy, IDegLira reduced levels of glycated haemoglobin (HbA1c; weighted mean differences (WMDs) 0.52%, 95% CI 0.33%-0.71%); fasting blood glucose (0.32 mg/dL, 0.14-0.50 mg/dL), and the nine-point self-measured plasma glucose (0.25 mmol/L, 0.25-0.36 mmol/L).
1 context sentence(design, population, supporting numbers)
Summary · context
Randomized controlled trials published in English that compared IDegLira with placebo or GLP-1 agonists or insulin in patients with T2DM were selected up to December 2022.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3801321503
04HumanNot a test of Liraglutide aloneSystematic reviewEfficacy outcome
In patients with type 2 diabetes, IDegLira was generally better than comparators in reaching HbA1c below 7.0% or 6.5% or less.
In plain wordsIn people with type 2 diabetes, more people reached HbA1c targets with the insulin degludec/liraglutide combination than with the comparator treatments.
Peptide
Liraglutide
Outcome
IncreaseAttainment of HbA1c below 7.0% or 6.5% or less
Study
n: not reported in source
Comparator
Insulin, GLP-1 receptor agonists or placebo (pooled)
Outcome group
Glycemic control · Metabolic and weight
Source sentences
Summary
Furthermore, IDegLira was generally better in the attainment of HbA1c < 7.0% or ≤6.5%, HbA1c < 7.0% or ≤6.5% without weight gain and/or without severe or blood glucose-confirmed hypoglycaemic episodes.
1 context sentence(design, population, supporting numbers)
Summary · context
Randomized controlled trials published in English that compared IDegLira with placebo or GLP-1 agonists or insulin in patients with T2DM were selected up to December 2022.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3801321504
05HumanNot a test of Liraglutide aloneSystematic reviewEfficacy outcome
In patients with type 2 diabetes, IDegLira was generally better than comparators in reaching HbA1c targets without weight gain and/or without severe or blood glucose-confirmed hypoglycaemia.
In plain wordsIn people with type 2 diabetes, more people reached HbA1c targets without weight gain or low blood sugar with the combination than with comparator treatments.
Peptide
Liraglutide
Outcome
IncreaseHbA1c target without weight gain and/or hypoglycaemia
Study
n: not reported in source
Comparator
Insulin, GLP-1 receptor agonists or placebo (pooled)
Outcome group
Glycemic control · Metabolic and weight
Source sentences
Summary
Furthermore, IDegLira was generally better in the attainment of HbA1c < 7.0% or ≤6.5%, HbA1c < 7.0% or ≤6.5% without weight gain and/or without severe or blood glucose-confirmed hypoglycaemic episodes.
1 context sentence(design, population, supporting numbers)
Summary · context
Randomized controlled trials published in English that compared IDegLira with placebo or GLP-1 agonists or insulin in patients with T2DM were selected up to December 2022.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3801321505
06HumanNot a test of Liraglutide aloneSystematic reviewEfficacy outcome
In patients with type 2 diabetes, IDegLira decreased systolic blood pressure versus comparators.
In plain wordsIn people with type 2 diabetes, the insulin degludec/liraglutide combination lowered systolic blood pressure compared with the comparator treatments.
Peptide
Liraglutide
Outcome
DecreaseSystolic blood pressure
Study
n: not reported in source
Comparator
Insulin, GLP-1 receptor agonists or placebo (pooled)
Outcome group
Blood pressure · Cardiovascular
Source sentences
Summary
In non-glycaemic efficacy aspects, IDegLira decreased systolic blood pressure but elevated heart rate.
1 context sentence(design, population, supporting numbers)
Summary · context
Randomized controlled trials published in English that compared IDegLira with placebo or GLP-1 agonists or insulin in patients with T2DM were selected up to December 2022.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3801321506
07HumanNot a test of Liraglutide aloneSystematic reviewSafety outcome
In patients with type 2 diabetes, IDegLira elevated heart rate versus comparators.
In plain wordsIn people with type 2 diabetes, the insulin degludec/liraglutide combination raised heart rate compared with the comparator treatments.
Peptide
Liraglutide
Outcome
IncreaseHeart rate
Study
n: not reported in source
Comparator
Insulin, GLP-1 receptor agonists or placebo (pooled)
Outcome group
Heart function · Cardiovascular
Source sentences
Summary
In non-glycaemic efficacy aspects, IDegLira decreased systolic blood pressure but elevated heart rate.
1 context sentence(design, population, supporting numbers)
Summary · context
Randomized controlled trials published in English that compared IDegLira with placebo or GLP-1 agonists or insulin in patients with T2DM were selected up to December 2022.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3801321507
08HumanNot a test of Liraglutide aloneSystematic reviewSafety outcome
In patients with type 2 diabetes, IDegLira was not associated with a higher risk of hypoglycaemia than other hypoglycaemic agents or placebo (RR 1.23).
In plain wordsIn people with type 2 diabetes, the insulin degludec/liraglutide combination did not raise the risk of low blood sugar compared with other agents or placebo.
Peptide
Liraglutide
Outcome
No significant changeHypoglycaemia risk
Study
n: not reported in source
Comparator
Insulin, GLP-1 receptor agonists or placebo (pooled)
Outcome group
Adverse events · Metabolic and weight
Measurements
RR
1.23 ratio
hypoglycaemia
Source sentences
Summary
In terms of safety outcomes, IDegLira did not appear to be associated with a risk of hypoglycaemia (RR 1.23, 0.85-1.78) and nocturnal hypoglycaemia (0.89, 0.52-1.52) occurring when compared with other hypoglycaemic agents or placebo.
1 context sentence(design, population, supporting numbers)
Summary · context
Randomized controlled trials published in English that compared IDegLira with placebo or GLP-1 agonists or insulin in patients with T2DM were selected up to December 2022.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3801321508
09HumanNot a test of Liraglutide aloneSystematic reviewSafety outcome
In patients with type 2 diabetes, IDegLira was not associated with a higher risk of nocturnal hypoglycaemia than other hypoglycaemic agents or placebo (RR 0.89).
In plain wordsIn people with type 2 diabetes, the insulin degludec/liraglutide combination did not raise the risk of night-time low blood sugar versus other agents or placebo.
Peptide
Liraglutide
Outcome
No significant changeNocturnal hypoglycaemia risk
Study
n: not reported in source
Comparator
Insulin, GLP-1 receptor agonists or placebo (pooled)
Outcome group
Adverse events · Metabolic and weight
Measurements
RR
0.89 ratio
nocturnal hypoglycaemia
Source sentences
Summary
In terms of safety outcomes, IDegLira did not appear to be associated with a risk of hypoglycaemia (RR 1.23, 0.85-1.78) and nocturnal hypoglycaemia (0.89, 0.52-1.52) occurring when compared with other hypoglycaemic agents or placebo.
1 context sentence(design, population, supporting numbers)
Summary · context
Randomized controlled trials published in English that compared IDegLira with placebo or GLP-1 agonists or insulin in patients with T2DM were selected up to December 2022.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3801321509

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 11:11 UTC
Study results updated
Version 1
9 Oct 2026, 03:05 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.